Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation_ [360p]
